A case of Paget's disease in hemodialysis

被引：0

作者：

Cianciolo, G. ^{[1
]}

La Manna, G. ^{[1
]}

Capelli, I. ^{[1
]}

Donati, G. ^{[1
]}

Persici, E. ^{[1
]}

Cuna, V. ^{[1
]}

Corsini, S. ^{[1
]}

Stefoni, S. ^{[1
]}

机构：

[1] S Orsola Univ Hosp, Nephrol Dialysis & Renal Transplantat Unit, I-40138 Bologna, Italy

来源：

CLINICAL NEPHROLOGY | 2010年 / 73卷 / 05期

关键词：

Paget's disease; hemodialysis; secondary hyperparathyroidism; bisphosphonates; paracalcitol; OSTEOCLAST FORMATION; BONE; CLODRONATE; ANALOGS; RANKL;

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Paget's disease is the second most common bone disease after osteoporosis and causes an excessive bone turnover. Moreover, chronic kidney failure causes an impairment of bone mineral metabolism and electrolytes and PTH homeostasis. As far as we know, this is the first reported case of Paget's disease in a hemodialysis patient: the patient was also affected by secondary hyperparathyroidism and was successfully treated with clodronate, cinacalcet and paracalcitol. The safety and efficacy of this combined therapy was periodically revised in a 12-month follow-up considering the common markers of bone turnover as well as the dosage of OPG, RANKL, IL-6 and MCSF, involved in the pathophysiology of Paget's disease.

引用

页码：403 / 407

页数：5

共 18 条

[1] Pharmacokinetics of clodronate in haemodialysis patients [J].

Ala-Houhala, I ;

Saha, H ;

Liukko-Sipi, S ;

Ylitalo, P ;

Pasternack, A .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (03) :699-705

[2] Serum osteoprotegerin and its ligand in Paget's disease of bone -: Relationship to disease activity and effect of treatment with bisphosphonates [J].

Alvarez, L ;

Peris, P ;

Guañabens, N ;

Vidal, S ;

Ros, I ;

Pons, F ;

Filella, X ;

Monegal, A ;

Muñoz-Gomez, J ;

Ballesta, AM .

ARTHRITIS AND RHEUMATISM, 2003, 48 (03) :824-828

[3] Cinacalcet hydrochloride (sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate [J].

Chertow, Glenn M. ;

Blumenthal, Samuel ;

Turner, Stewart ;

Roppolo, Michael ;

Stern, Leonard ;

Chi, Eric M. ;

Reed, John .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (02) :305-312

[4] Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin [J].

Collin-Osdoby, P .

CIRCULATION RESEARCH, 2004, 95 (11) :1046-1057

[5] Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients [J].

Dobnig, H ;

Hofbauer, LC ;

Viereck, V ;

Obermayer-Pietsch, B ;

Fahrleitner-Pammer, A .

OSTEOPOROSIS INTERNATIONAL, 2006, 17 (05) :693-703

[6] Role of vitamin D deficiency in chronic kidney disease [J].

Gal-Moscovici, Arica ;

Sprague, Stuart M. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 :V91-V94

[7] Novel vitamin D3 analogs, 1α, 25(OH)2D3-26, 23-lactam (DLAMs), antagonize bone resorption via suppressing RANKL expression in osteoblasts [J].

Inada, Masaki ;

Tsukamoto, Kazuki ;

Hirata, Michiko ;

Takita, Morichika ;

Nagasawa, Kazuo ;

Miyaura, Chisato .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 372 (03) :434-439

[8] Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1α,25-dihydroxyvitamin D3 from pagetic bone marrow cells [J].

Ishizuka, S ;

Kurihara, N ;

Miura, D ;

Takenouchi, K ;

Cornish, J ;

Cundy, T ;

Reddy, SV ;

Roodman, GD .

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2004, 89-90 (1-5) :331-334

[9]

Josse RG, 2007, CLIN INVEST MED, V30, pE210

[10] Duration of response with oral clodronate in Paget's disease of bone [J].

Khan, SA ;

McCloskey, EV ;

Nakatsuka, K ;

Orgee, J ;

Coombes, GM ;

Kanis, JA .

BONE, 1996, 18 (02) :185-190

← 1 2 →